| | Study ID | Sample | Age (years, mean) | Interventions | Duration | Outcomes | | Size (T/C) | T | C | T | C | In months |
| | Lehui [11] | 100 (50/50) | 54.3 ± 3.2 | 54.8 ± 3.5 | DHJSD | Alendronate (10 mg, qd, po) | 3 | ① | | Yumei [12] | 60 (30/30) | 64.0 ± 6.2 | 65.0 ± 3.3 | DHJSD + control | Zoledronic acid (4 mg, Q20 d, ivgtt) | 3 | ①, ②, (a), ④, ⑤, and ⑥ | | Shangzhi and Juntao [13] | 70 (35/35) | 63.0 ± 3.3 | 64.0 ± 6.2 | DHJSD | Alendronate (70 mg, qw, po) | 3 | ①, ②, (a), ③, and ④; NBAP | | Jinwei et al. [14] | 120 (60/60) | 67 ± 5 | 66 ± 6 | DHJSD + control | Caltrate D (600 mg, qn, po) | 3 | ①, ②, (a, b), ④, ⑤, ⑥, and ⑦ | | Shaofeng [15] | 100 (50/50) | 58.87 ± 11.08 | 58.64 ± 12.21 | DHJSD + control | Zoledronic acid (5 mg, -, ivgtt) | 12 | ①, ②, ③, and④ | | Keming et al. [16] | 60 (30/30) | 57.3 | 57.3 | A : DHJSD + control | C: zoledronic acid (4 mg, Q30 d, ivgtt) | 12 | ①, ②, (a), ③, ④, and ⑦ | | Keming et al. [16] | 60 (30/30) | 57.3 | 57.3 | B : DHJSD | C: zoledronic acid (4 mg, Q30 d, ivgtt) | 12 | ①, ②, (a), ③, ④, and ⑦ | | Yang et al. [17] | 80 (40/40) | 53.69 ± 7.76 | 52.82 ± 7.93 | DHJSD + control | Caltrate D (600 mg, 1-2 tablets, qn, po), | 3 | ①, ②, (a, b), and ③; CTX |
|
|
Note. ①, clinical effectiveness; ②, BMD (a, lumbar spine and b, femoral neck); ③, BGP; ④, E2; ⑤, P; ⑥, Ca; and ⑦, ALP, the information is lost; NBAP, bone alkaline phosphatase; CTX, c-terminal crosslinking telopeptide.
|
